December II, 2023

During an in-person Targeted Oncology™ Clinical Case Forum event in New Jersey, Tiffany Traina, MD, discussed the role of antibody-drug conjugates in advanced breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed issues related to dosing and management of patients receiving ruxolitinib for myelofibrosis.

Ruta D. Rao, MD, and Virginia G. Kaklamani, MD, discuss with participants the case of a patient with breast cancer who has received multiple lines of therapy and what the next steps are for her treatment.

The approval of talquetamab, a GPRC5D-targeted bispecific T-cell engager, led to discussions in 2 separate Case-Based Roundtable events on therapy sequencing selection, toxicity, and outpatient treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Lisa Barroilhet, MD, MS, discussed recent trials that are relevant to a patient with recurrent endometrial cancer who relapsed less than a year after a complete response to doublet chemotherapy.

Wayne Jonas, MD, of the Healing Works Foundation, spoke with Targeted Oncology about how oncologists can bridge the communication gap between them and patients and promote integrative care.

At a live virtual event Richard Kim, MD, discussed treating patients with hepatocellular carcinoma and how the treatment approach to this disease has changed.